EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease

BACKGROUND: Gocovri(®) (amantadine) extended release capsules are approved for the treatment of dyskinesia in patients with Parkinson’s disease (PD) receiving levodopa-based therapy. OBJECTIVE: To evaluate the long-term safety, tolerability, and efficacy of Gocovri in patients with PD experiencing l...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanner, Caroline M., Pahwa, Rajesh, Hauser, Robert A., Oertel, Wolfgang H., Isaacson, Stuart H., Jankovic, Joseph, Johnson, Reed, Chernick, Dustin, Hubble, Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2020
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242830/
https://www.ncbi.nlm.nih.gov/pubmed/31929122
http://dx.doi.org/10.3233/JPD-191841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242830/
https://www.ncbi.nlm.nih.gov/pubmed/31929122
http://dx.doi.org/10.3233/JPD-191841

Ejemplares similares